Pascal Gedeon
Medical · Boynton Beach, FLNPI 1194872317
Payments from drug & device makers
Across 186 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$859
- Viiv Healthcare Company$721
- Merck$386
- Theratechnologies Inc.$248
- Exact Sciences$208
- Johnson & Johnson$188
- plus $417 from 8 others
What the payments were for
- Food & beverage$2,74891%
- Education$2779%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 52 | $859 |
| Viiv Healthcare Company | 71 | $721 |
| Merck | 17 | $386 |
| Theratechnologies Inc. | 11 | $248 |
| Exact Sciences | 9 | $208 |
| Johnson & Johnson(2 entities) | 11 | $188 |
| Janssen Products, LP | 2 | $184 |
| GSK | 5 | $82 |
| Neurocrine Biosciences, Inc. | 2 | $44 |
| Cranial Technologies, Inc | 2 | $29 |
| EMD Serono, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Pfizer | 1 | $19 |
| AbbVie | 1 | $18 |
How this compares
$3,026 in reported general payments places this provider in the 75th percentile of 2,031 medical providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 233 | $886,724 |
| DovatoDolutegravir Sodium/Lamivudine | 147 | $413,986 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 85 | $368,418 |
| TivicayDolutegravir Sodium | 164 | $365,305 |
| RukobiaFostemsavir Tromethamine | 31 | $282,681 |
| JulucaDolutegravir/Rilpivirine | 48 | $162,735 |
| DescovyEmtricitabine/Tenofov Alafenam | 70 | $159,741 |
| PifeltroDoravirine | 74 | $123,829 |
| CabenuvaCabotegravir/Rilpivirine | 16 | $97,638 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 23 | $79,713 |
| PrezcobixDarunavir/Cobicistat | 19 | $45,417 |
| OzempicSemaglutide | 41 | $45,225 |
| JardianceEmpagliflozin | 41 | $39,291 |
| JanuviaSitagliptin Phosphate | 19 | $16,380 |
| MounjaroTirzepatide | 11 | $13,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Tivicay, Rukobia, Juluca, Cabenuva | $721 | $1,322,345406 claims |
| GileadBiktarvy, Descovy | $859 | $1,046,465303 claims |
| Janssen Products, LPSymtuza | $184 | $368,41885 claims |
| MerckPifeltro, Januvia | $386 | $140,20993 claims |
| Johnson & JohnsonPrezcobix | $188 | $45,41719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,031 medical providers in Florida.
Other medical in Boynton Beach
- Aaron CohenBoynton Beach$28K
- Douglas LeemanBoynton Beach$16K
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
- Kathleen TrummerWellington$166K
- Sandra SnyderTampa$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.